Clinical and Experimental Vaccine Research

The Korean Vaccine Society (대한백신학회)
권호 표지
DOI QR코드

DOI QR Code

Immunization of mice with chimeric protein-loaded aluminum hydroxide and selenium nanoparticles induces reduction of Brucella melitensis infection in mice

  • Tahereh Goudarzi (Department of Genetics, Faculty of Biological Sciences and Technology, Shahid Ashrafi Esfahani University) ;
  • Morteza Abkar (Department of Genetics, Faculty of Biological Sciences and Technology, Shahid Ashrafi Esfahani University) ;
  • Zahra Zamanzadeh (Department of Genetics, Faculty of Biological Sciences and Technology, Shahid Ashrafi Esfahani University) ;
  • Mahdi Fasihi-Ramandi (Molecular Biology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences)
  • Received : 2023.01.11
  • Accepted : 2023.10.16
  • Published : 2023.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Due to the many problems with commercially available vaccines, the production of effective vaccines against brucellosis is a necessity. The aim of this study was to evaluate the immune responses caused by the chimeric protein consisting of trigger factor, Bp26, and Omp31 (TBO) along with aluminum hydroxide (AH/TBO) and selenium (Se/TBO) nanoparticles (NPs) as adjuvants in mouse model. Materials and Methods: Recombinant antigen expression was induced in Escherichia coli BL21 (DE3) bacteria using IPTG (isopropyl-d-1-thiogalactopyranoside). Purification and characterization of recombinant protein was conducted through NiFe3O4 NPs, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and Western blot. NP characteristics, including morphology and particle size, were measured in vitro. The recombinant TBO was loaded on to AH and Se NPs and were administered subcutaneously. After mice immunization, measurement of antibody titter and protection assay was performed. Results: The average sizes of AH and Se NPs were about 60 nm and 150 nm, respectively. The enzyme-linked immunosorbent assay results showed that the serum of mice immunized by subcutaneous injection with both nanovaccines produced significant immunoglobulin G (IgG) responses against the chimeric antigen. The results of TBO-specific IgG isotype (IgG2a/IgG1) analysis showed that both AH and Se NPs induced a type to T-helper immune response. In addition, the results of the challenge with the pathogenic strain of Brucella melitensis 16M showed that vaccinated mice with AH/TBO NPs indicated a higher reduction of bacterial culture than immunized mice with Se/TBO NPs and TBO alone. Conclusion: The results showed that AH NPs carrying chimeric antigen can be a promising vaccine candidate against brucellosis by producing protective immunity.

Keywords

References

  1. Karevan G, Ahmadi K, Taheri RA, Fasihi-Ramandi M. Immunogenicity of glycine nanoparticles containing a chimeric antigen as brucella vaccine candidate. Clin Exp Vaccine Res 2021;10:35-43. 
  2. Maleki M, Salouti M, Shafiee Ardestani M, Talebzadeh A. Preparation of a nanovaccine against brucella melitensis M16 based on PLGA nanoparticles and oligopolysaccharide antigen. Artif Cells Nanomed Biotechnol 2019;47:4248-56. 
  3. Sadeghi Z, Fasihi-Ramandi M, Azizi M, Bouzari S. Mannosylated chitosan nanoparticles loaded with FliC antigen as a novel vaccine candidate against brucella melitensis and brucella abortus infection. J Biotechnol 2020;310:89-96. 
  4. Abkar M, Lotfi AS, Amani J, et al. Survey of Omp19 immunogenicity against Brucella abortus and Brucella melitensis: influence of nanoparticulation versus traditional immunization. Vet Res Commun 2015;39:217-28. 
  5. Shim S, Soh SH,Im YB, et al. Elicitation of Th1/Th2 related responses in mice by chitosan nanoparticles loaded with brucella abortus malate dehydrogenase, outer membrane proteins 10 and 19. Int J Med Microbiol 2020;310:151362. 
  6. Abkar M, Fasihi-Ramandi M, Kooshki H, Sahebghadam LotfiA. Oral immunization of mice with Omp31-loaded N-trimethyl chitosan nanoparticles induces high protection against brucella melitensis infection. Int J Nanomedicine 2017;12:8769-78. 
  7. Razei A,Cheraghali AM, Saadati M, et al. Gentamicin-loaded chitosan nanoparticles improve its therapeutic effects on brucella-infected J774A.1 murine cells. Galen Med J 2019;8:e1296. 
  8. Abkar M, Fasihi-Ramandi M, Kooshki H, Lotfi AS. Intraperitoneal immunization with urease loaded N-trimethyl chitosan nanoparticles elicits high protection against brucella melitensis and brucella abortus infections. Immunol Lett 2018;199:53-60. 
  9. Abdollahi A, Mansouri S, Amani J, Fasihi-Ramandi M, Moradi M. Immunoreactivity evaluation of a new recombinant chimeric protein against brucella in the murine model. Iran J Microbiol 2016;8:193-202. 
  10. Kaushik P, Singh DK, Kumar SV, et al. Protection of mice against brucella abortus 544 challenge by vaccination with recombinant OMP28 adjuvanted with CpG oligonucleotides. Vet Res Commun 2010;34:119-32. 
  11. Huy TX, Nguyen TT, Reyes AW, et al. Immunization with a combination of four recombinant brucella abortus proteins Omp16, Omp19, Omp28, and L7/L12 induces T helper 1 immune response against virulent B. abortus 544 infection in BALB/c mice. Front Vet Sci 2021;7:577026. 
  12. Ghasemi A, Salari MH, Zarnani AH, et al.Immune reactivity of brucella melitensis-vaccinated rabbit serum with recombinant Omp31 and DnaK proteins. Iran J Microbiol 2013;5:19-23. 
  13. Yao L, Wu CX, Zheng K, et al. Immunogenic response to a recombinant pseudorabies virus carrying bp26 gene of brucella melitensis in mice. Res Vet Sci 2015;100:61-7. 
  14. Onate AA, Cespedes S, Cabrera A, et al. A DNA vaccine encoding Cu,Zn superoxide dismutase of brucella abortus induces protective immunity in BALB/c mice. Infect Immun 2003;71:4857-61. 
  15. Estein SM, Cheves PC, Fiorentino MA,Cassataro J, Paolicchi FA, Bowden RA. Immunogenicity of recombinant Omp31 from brucella melitensis in rams and serum bactericidal activity against B. ovis. Vet Microbiol 2004;102:203-13. 
  16. Cassataro J, Velikovsky CA,Bruno L, et al.Improved immunogenicity of a vaccination regimen combining a DNA vaccine encoding brucella melitensis outer membrane protein 31 (Omp31) and recombinant Omp31 boosting. Clin Vaccine Immunol 2007;14:869-74. 
  17. Cassataro J, Pasquevich KA, Estein SM, et al. A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination. Vaccine 2007;25:4437-46. 
  18. Clausse M, Diaz AG, Ghersi G, et al. The vaccine candidate BLSOmp31 protects mice against brucella canis infection. Vaccine 2013;31:6129-35. 
  19. Masjedian Jezi F, Razavi S, Mirnejad R, Zamani K. Immunogenic and protective antigens of brucella as vaccine candidates. Comp Immunol Microbiol Infect Dis 2019;65:29-36. 
  20. Ghasemi A, Jeddi-Tehrani M, Mautner J, Salari MH, ZarnaniAH. Simultaneous immunization of mice with Omp31 and TF provides protection against brucella melitensis infection. Vaccine 2015;33:5532-8. 
  21. Yang X, Walters N, Robison A, Trunkle T, Pascual DW. Nasal immunization with recombinant brucella melitensis bp26 and trigger factor with cholera toxin reduces B. melitensis colonization. Vaccine 2007;25:2261-8. 
  22. Abkar M, Alamian S, Sattarahmady N. A comparison between adjuvant and delivering functions of calcium phosphate, aluminum hydroxide and chitosan nanoparticles, using a model protein of brucella melitensis Omp31. Immunol Lett 2019;207:28-35. 
  23. Rana T. Nano-selenium on reproduction and immunocompetence: an emerging progress and prospect in the productivity of poultry research. Trop Anim Health Prod 2021;53:324. 
  24. Molanouri Shamsi M, Chekachak S, Soudi S, et al. Effects of exercise training and supplementation with selenium nanoparticle on T-helper 1 and 2 and cytokine levels in tumor tissue of mice bearing the 4 T1 mammary carcinoma. Nutrition 2019;57:141-7. 
  25. Raahati Z, Bakhshi B, Najar-Peerayeh S. Selenium nanoparticles induce potent protective immune responses against vibrio cholerae WC vaccine in a mouse model. J Immunol Res 2020;2020:8874288. 
  26. Mahdavi M, Mavandadnejad F, Yazdi MH, et al. Oral administration of synthetic selenium nanoparticles induced robust Th1 cytokine pattern after HBs antigen vaccination in mouse model. JInfect Public Health 2017;10:102-9. 
  27. Glenny AT. The antigenic value of toxoid precipitated by potassium alum. J Pathol Bacteriol 1926;29:38-40. 
  28. Gogoi H, Mani R, Malik A, Sehrawat P, Bhatnagar R. Coadministration of aluminium hydroxide nanoparticles and protective antigen domain 4 encapsulated non-ionic surfactant vesicles show enhanced immune response and superior protection against anthrax. Vaccines (Basel) 2020;8:571. 
  29. Amini Y, Moradi B, Fasihi-Ramandi M.Aluminum hydroxide nanoparticles show strong activity to stimulate Th-1 immune response against tuberculosis. Artif Cells Nanomed Biotechnol 2017;45:1331-5. 
  30. Amani J, Ghasemi A, Ranjbar R, Shabani M, Zandemami M, Golmohammadi R. Immune reactivity of sera obtained from brucellosis patients and vaccinated-rabbits to a fusion protein from brucella melitensis. Iran J Basic Med Sci 2015;18:350-5. 
  31. GhasemiA, Ranjbar R,AmaniJ.In silico analysis of chimeric TF, Omp31 and BP26 fragments of brucella melitensis for development of a multi subunit vaccine candidate. Iran J Basic Med Sci 2014;17:172-80. 
  32. Ghasemi A, Salari MH, Zarnani AH, et al. Immunogenicity assessment of brucella mellitensis HSP and TF proteins by immunized rabbit serum.Iran J Allergy Asthma Immunol 2013;12:192-4. 
  33. He P, Zou Y, Hu Z. Advances in aluminum hydroxide-based adjuvant research and its mechanism. Hum Vaccin Immunother 2015;11:477-88. 
  34. Morcol T, Hurst BL, Tarbet EB. Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice. Vaccine 2017;35(35 Pt B):4569-77. 
  35. Morcol T, Nagappan P, Bell SJ, Cawthon AG. Influenza A(H5N1) virus subunit vaccine administered with CaPNP adjuvant induce high virus neutralization antibody titers in mice. AAPS PharmSciTech 2019;20:315. 
  36. Pagheh AS, Sarvi S, Gholami S, et al. Protective efficacy induced by DNA prime and recombinant protein boost vaccination with Toxoplasma gondii GRA14 in mice. Microb Pathog 2019;134:103601. 
  37. Yousefi S, Abbassi-Daloii T, Tahmoorespur M, Sekhavati MH. Nanoparticle or conventional adjuvants: which one improves immune response against Brucellosis? Iran J Basic Med Sci 2019;22:360-6. 
  38. Shojaei M, Tahmoorespur M, Soltani M, Sekhavati MH. Immunogenicity evaluation of plasmids encoding Brucella melitensis Omp25 and Omp31 antigens in BALB/c mice. Iran J Basic Med Sci 2018;21:957-64. 
  39. Sokolovska A, Hem SL, HogenEsch H. Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants. Vaccine 2007;25:4575-85. 
  40. Dodangeh S, Fasihi-Ramandi M, Daryani A, et al. Protective efficacy by a novel multi-epitope vaccine, including MIC3, ROP8, and SAG1, against acute Toxoplasma gondii infection in BALB/c mice. Microb Pathog 2021;153:104764.